Evidence map›Paper›PMID 42384969›Full record

ArticleRevista da Associacao Medica Brasileira (1992)2026

The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease.

Süleyman Karaköse, Beyza Doğan, Fatih Ergül, İbrahim Güney

Abstract read
In one paragraph

Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Süleyman KaraköseUniversity of Health Science, Konya City Hospital, Department of Nephrology - Konya, Turkey.ORCID http://orcid.org/0000-0003-4680-7435
Beyza DoğanUniversity of Health Science, Konya City Hospital, Department of Nephrology - Konya, Turkey.ORCID http://orcid.org/0000-0003-0461-1231
Fatih ErgülUniversity of Health Science, Konya City Hospital, Department of Nephrology - Konya, Turkey.ORCID http://orcid.org/0000-0001-7498-9710
İbrahim GüneyUniversity of Health Science, Konya City Hospital, Department of Nephrology - Konya, Turkey.ORCID http://orcid.org/0000-0002-1646-2811

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population.

methodsWe retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data.

resultsFollowing 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure.

conclusionSodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.

Indexed as

Diabetic NephropathiesHemoglobinsRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAgedAnemiaBlood PressureFemaleGlomerular Filtration RateHematocritHumansMaleMiddle AgedRetrospective StudiesTime FactorsHemoglobinsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID42384969
PMCPMC13316855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.